Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Sanofi and Lexicon Pharmaceuticals to Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes

Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20

November 6, 2015 6:25 AM EST

Sanofi (NYSE: SNY) will host an Investor Relations seminar today ('Meet Sanofi Management') at which it will set out its strategic roadmap for the period 2015-2020 and its ambition to become the pre-eminent diversified global healthcare company. Through a process of refocusing and reshaping the organisation and investing in key launches and businesses, Sanofi expects to deliver a sales compound annual growth rate (CAGR) of between +3% and +4%4 over 2015-2020, with a target of mid-single digit... More